These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 15764851)

  • 1. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
    van Leth F; Andrews S; Grinsztejn B; Wilkins E; Lazanas MK; Lange JM; Montaner J;
    AIDS; 2005 Mar; 19(5):463-71. PubMed ID: 15764851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
    Leth FV; Kappelhoff BS; Johnson D; Losso MH; Boron-Kaczmarska A; Saag MS; Livrozet JM; Hall DB; Leith J; Huitema AD; Wit FW; Beijnen JH; Lange JM;
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):232-9. PubMed ID: 16545009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
    Keiser P; Nassar N; White C; Koen G; Moreno S
    HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
    van Leth F; Huisamen CB; Badaro R; Vandercam B; de Wet J; Montaner JS; Hall DB; Wit FW; Lange JM;
    J Acquir Immune Defic Syndr; 2005 Mar; 38(3):296-300. PubMed ID: 15735447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.
    Manosuthi W; Sungkanuparph S; Vibhagool A; Rattanasiri S; Thakkinstian A
    HIV Med; 2004 Mar; 5(2):105-9. PubMed ID: 15012650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
    Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals.
    Núñez M; Soriano V; Martín-Carbonero L; Barrios A; Barreiro P; Blanco F; García-Benayas T; González-Lahoz J
    HIV Clin Trials; 2002; 3(3):186-94. PubMed ID: 12032877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
    Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
    Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.
    van Leth F; Conway B; Laplumé H; Martin D; Fisher M; Jelaska A; Wit FW; Lange JM;
    Antivir Ther; 2004 Oct; 9(5):721-8. PubMed ID: 15535409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
    Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.
    Patel AK; Pujari S; Patel K; Patel J; Shah N; Patel B; Gupte N
    J Assoc Physicians India; 2006 Dec; 54():915-8. PubMed ID: 17334006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.
    Mwesigire DM; Wu AW; Martin F; Katamba A; Seeley J
    BMC Health Serv Res; 2015 Jul; 15():292. PubMed ID: 26216221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.
    Ananworanich J; Moor Z; Siangphoe U; Chan J; Cardiello P; Duncombe C; Phanuphak P; Ruxrungtham K; Lange J; Cooper DA
    AIDS; 2005 Jan; 19(2):185-92. PubMed ID: 15668544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort.
    Li T; Dai Y; Kuang J; Jiang J; Han Y; Qiu Z; Xie J; Zuo L; Li Y
    PLoS One; 2008; 3(12):e3918. PubMed ID: 19081791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
    Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
    J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
    Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.